RGENREPLIGEN CORP
Biological Products, (no Diagnostic Substances)
- Revenue
- $738M
- 16% YoY
- Operating margin
- 7.5%
- 235% YoY
- EBITDA
- $134M
- 287% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -1.3×
- −$171M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear240% of net incomeCash flow under 80% of net income
- Dilutive SBCClear4% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear38% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $671M | $802M | $632M | $634M | $738M | 16% |
| Operating income | $167M | $225M | $48M | −$35M | $55M | 257% |
| Net income | $128M | $186M | $36M | −$26M | $49M | 292% |
| Operating cash flow | $119M | $172M | $114M | $175M | $117M | 33% |
| Capex | $67M | $85M | $36M | $26M | $24M | 8.4% |
| Stock-based comp | $28M | $27M | $26M | $48M | $33M | 32% |
| Buybacks | $0 | $0 | $14M | $0 | $0 |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $5M · 6
- Net
- −$5M
Pay vs performance
No pay-versus-performance disclosure yet.